Gili Hart
Direktor/Vorstandsmitglied bei ENLIVEX THERAPEUTICS LTD.
Vermögen: 4 591 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Avri Havron | M | 76 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | 19 Jahre |
| Yosef Cohen | M | 49 | 14 Jahre | |
| Pini Mandel | M | 46 | 14 Jahre | |
| Shai Novik | M | 58 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 23 Jahre |
| Roger Pomerantz | M | 67 | 4 Jahre | |
| Oren Hershkovitz | M | 47 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 8 Jahre |
| Amichai Helman | M | 45 | 3 Jahre | |
| Alisa Lask | F | 53 | 3 Jahre | |
| Joseph Zarzewsky | M | 63 | 5 Jahre | |
| Hugh Evans | M | 58 | 3 Jahre | |
| Andrew Singer | M | 53 | 1 Jahre | |
| Herzel Naftali Laks | M | 48 | 2 Jahre | |
| Keren Primor Cohen | F | 48 | 3 Jahre | |
| Elan Penn | M | 72 | 6 Jahre | |
| Dror Mevorach | M | 68 | 15 Jahre | |
| Einat Galamidi | M | - | 2 Jahre | |
| Iris Tavor | F | - | - | |
| Hadas Dreiher-Horowitz | F | 47 | 3 Jahre | |
| Elana Gazal | M | 49 | 2 Jahre | |
| Avri Katzir | M | 49 | 4 Jahre | |
| Veronique Amor-Baroukh | M | - | - | |
| Or Stokelman | M | 38 | 4 Jahre | |
| Sigal Arad | M | - | - | |
| Yeshai Kav | M | 45 | 6 Jahre | |
| Stanley Fiel | M | - |
SpliSense Ltd.
 SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | - |
| Shachar Shlosberger | F | 47 | 8 Jahre | |
| Oren Elmaliah | M | 40 | 7 Jahre | |
| Shay Lang | M | - | 1 Jahre | |
| Gal Yaffe | M | 48 | 2 Jahre | |
| Daniel Spira | M | 69 | 3 Jahre | |
| Gidon Zairi | M | - |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | 4 Jahre |
| Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 Jahre |
| Adam Logal | M | 46 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 10 Jahre |
| Brian Schwartz | M | 52 | 4 Jahre | |
| Avia Ben Hamo | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Peter L. Coker | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Phillip Frost | M | 87 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 Jahre |
| Adam Stern | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Udi Eyal Fima | M | 60 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Bernhard Kirschbaum | M | 65 | - | |
| David Tsur | M | 73 | 2 Jahre | |
| David Hochman | M | 48 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 Jahre |
| Michel Moise Habib | M | 57 | - | |
| Scott Burell | M | 59 | 2 Jahre | |
| Marian Gorecki | M | 83 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 9 Jahre |
| Jane Hsaio | M | 77 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 6 Jahre |
| Shomrat Shurtz | F | 57 | 3 Jahre | |
| Michal Roytman | M | 39 | - | |
| Hyun Gyu Lee | M | - | - | |
| Shmuel Hess | M | 51 | - | |
| Sangwoo Lee | M | 52 | 6 Jahre | |
| Baruch Halpert | M | 57 | - | |
| Revital Mandil–Levin | M | 49 | 1 Jahre | |
| Steven Rubin | M | 63 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Eugene Bauer | M | 81 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Jonathan Rigby | M | 56 | - | |
| Robert F. Mauer | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 1 Jahre |
| Joel Kanter | M | 67 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | - |
| Wolfgang Ruttenstorfer | M | 73 | 1 Jahre | |
| Alastair Clemow | M | 72 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 2 Jahre |
| Marina Gofman Feler | F | 35 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Israel | 61 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
